Principal Investigator
Danielle Shpiner
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240294
Clinical Trial Summary
A randomized, double-blind, placebo-controlled, Phase 2 study to assess the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) to slow the disease progression of progressive supranuclear palsy (PSP) (PROSPER)
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Silvia Vargas Parra
Phone Number
+1 (305) 2433647
Email
s.vargasparra@miami.edu